Fel d 1-derived T cell peptide therapy induces recruitment of CD4+CD25+;: CD4+ interferon-γ+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects
Fel d 1-derived T cell peptide therapy induces recruitment of CD4+CD25+;: CD4+ interferon-γ+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects
复制标题
DOI：
10.1111/j.1365-2222.2005.02143.x
复制
发表时间：
2005-01-01
影响因子：
6.1
通讯作者：
Larché, M
中科院分区：
文献类型：
--
作者：
Alexander, C;Ying, S;Larché, M
背景全变应原提取物的特异性免疫治疗与局部聚集的干扰素-γ(+)和CD25(+)细胞有关，表明激活的T辅助细胞1型(Th1)和/或T调节细胞的募集。我们研究了T细胞肽治疗前后变应原诱导的晚期皮肤活检，以寻找Th1、T辅助细胞2型(Th2)和T调节细胞局部募集模式改变的证据。目的评价T细胞肽治疗对变应原诱导的皮肤晚期反应的影响。方法8例猫过敏性哮喘患者每隔14天皮内注射合成FEL-1衍生肽。结果FEL-d-1多肽可降低气道高反应性(P=0.02)，抑制全猫变应原晚期皮肤反应(LPCR)(P=0.03)。这与治疗后皮肤中CD4(+)/干扰素-γ(+)(P=0.03)和CD4(+)/CD25(+)细胞的数量显著增加(P=0.04)有关，但与CD4(+)/IL-10(+)或CD4(+)/CTLA-4(+)细胞的数量无关。
Background Specific immunotherapy with whole allergen extracts is associated with local accumulation of IFN-gamma(+) and CD25(+) cells indicating recruitment of activated T-helper type 1 (Th1) and/or T regulatory cells. We have studied allergen-induced, late-phase skin biopsies before and after T cell peptide therapy for evidence of alterations in the pattern of local recruitment of Th1, T-helper type 2 (Th2) and T regulatory cells.Objective To evaluate the effect of T cell peptide therapy on the allergen-induced cutaneous late-phase reaction.Methods Increasing doses of synthetic Fel d 1-derived peptides were administered (by intradermal injection) to eight cat-allergic asthmatics at 14-day intervals. Twenty-four-hour skin biopsies were taken from whole cat allergen- and diluent-injected sites, before and after treatment and studied by immunohistochemistry and in situ hybridization.Results Fel-d 1 peptides decreased airway hyper-responsiveness (P=0.02) and inhibited the late-phase cutaneous reaction (LPCR) to whole cat allergen (P=0.03). This was associated with significant increases (post- vs. pre-treatment) in the number of cutaneous CD4(+)/IFN-gamma(+) (P=0.03) and CD4(+)/CD25(+) cells (P=0.04), but not in CD4(+)/IL-10(+) or CD4(+)/CTLA-4(+) cells.Conclusions Treatment with allergen-derived T cell peptides results in allergen-dependent recruitment to the skin of Th1, rather than T regulatory cells, to cutaneous late-phase reaction sites.